Cover Image
Market Research Report

Cognitive Impairment - Pipeline Review, H2 2016

Published by Global Markets Direct Product code 199740
Published Content info 288 Pages
Immediate Delivery Available
Price
Back to Top
Cognitive Impairment - Pipeline Review, H2 2016
Published: September 21, 2016 Content info: 288 Pages
Description

Summary

Global Markets Direct's, 'Cognitive Impairment - Pipeline Review, H2 2016', provides an overview of the Cognitive Impairment pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Cognitive Impairment, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Cognitive Impairment and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Cognitive Impairment
  • The report reviews pipeline therapeutics for Cognitive Impairment by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Cognitive Impairment therapeutics and enlists all their major and minor projects
  • The report assesses Cognitive Impairment therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Cognitive Impairment

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Cognitive Impairment
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Cognitive Impairment pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Product Code: GMDHC8469IDB

Table of Contents

  • Table of Contents
  • Introduction
  • Cognitive Impairment Overview
  • Therapeutics Development
  • Cognitive Impairment - Therapeutics under Development by Companies
  • Cognitive Impairment - Therapeutics under Investigation by Universities/Institutes
  • Cognitive Impairment - Pipeline Products Glance
  • Cognitive Impairment - Products under Development by Companies
  • Cognitive Impairment - Products under Investigation by Universities/Institutes
  • Cognitive Impairment - Companies Involved in Therapeutics Development
  • Cognitive Impairment - Therapeutics Assessment
  • Drug Profiles
  • Cognitive Impairment - Dormant Projects
  • Cognitive Impairment - Discontinued Products
  • Cognitive Impairment - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Cognitive Impairment, H2 2016
  • Number of Products under Development for Cognitive Impairment - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Development by Companies, H2 2016 (Contd..1)
  • Number of Products under Development by Companies, H2 2016 (Contd..2)
  • Number of Products under Development by Companies, H2 2016 (Contd..3)
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Comparative Analysis by Unknown Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Products under Development by Companies, H2 2016 (Contd..2)
  • Products under Development by Companies, H2 2016 (Contd..3)
  • Products under Development by Companies, H2 2016 (Contd..4)
  • Products under Development by Companies, H2 2016 (Contd..5)
  • Products under Development by Companies, H2 2016 (Contd..6)
  • Products under Investigation by Universities/Institutes, H2 2016
  • Cognitive Impairment - Pipeline by AbbVie Inc, H2 2016
  • Cognitive Impairment - Pipeline by Addex Therapeutics Ltd, H2 2016
  • Cognitive Impairment - Pipeline by AgeneBio Inc., H2 2016
  • Cognitive Impairment - Pipeline by Amarantus Bioscience Holdings, Inc., H2 2016
  • Cognitive Impairment - Pipeline by Astellas Pharma Inc., H2 2016
  • Cognitive Impairment - Pipeline by AstraZeneca Plc, H2 2016
  • Cognitive Impairment - Pipeline by Avraham Pharmaceuticals Ltd., H2 2016
  • Cognitive Impairment - Pipeline by Boehringer Ingelheim GmbH, H2 2016
  • Cognitive Impairment - Pipeline by Bristol-Myers Squibb Company, H2 2016
  • Cognitive Impairment - Pipeline by Cardax, Inc., H2 2016
  • Cognitive Impairment - Pipeline by Cerecor Inc., H2 2016
  • Cognitive Impairment - Pipeline by CereSpir Incorporated, H2 2016
  • Cognitive Impairment - Pipeline by Cognition Therapeutics, Inc., H2 2016
  • Cognitive Impairment - Pipeline by Confluence Pharmaceuticals LLC, H2 2016
  • Cognitive Impairment - Pipeline by Coronis Partners Ltd., H2 2016
  • Cognitive Impairment - Pipeline by Cortice Biosciences, Inc., H2 2016
  • Cognitive Impairment - Pipeline by Eisai Co., Ltd., H2 2016
  • Cognitive Impairment - Pipeline by Eli Lilly and Company, H2 2016
  • Cognitive Impairment - Pipeline by Ensol Biosciences Inc., H2 2016
  • Cognitive Impairment - Pipeline by FORUM Pharmaceuticals Inc., H2 2016
  • Cognitive Impairment - Pipeline by Genzyme Corporation, H2 2016
  • Cognitive Impairment - Pipeline by H. Lundbeck A/S, H2 2016
  • Cognitive Impairment - Pipeline by Heptares Therapeutics Limited, H2 2016
  • Cognitive Impairment - Pipeline by IntelGenx Corp., H2 2016
  • Cognitive Impairment - Pipeline by Intra-Cellular Therapies, Inc., H2 2016
  • Cognitive Impairment - Pipeline by Iproteos S.L., H2 2016
  • Cognitive Impairment - Pipeline by Krenitsky Pharmaceuticals Inc., H2 2016
  • Cognitive Impairment - Pipeline by Luc Therapeutics, Inc., H2 2016
  • Cognitive Impairment - Pipeline by Merck & Co., Inc., H2 2016
  • Cognitive Impairment - Pipeline by Nanotherapeutics, Inc., H2 2016
  • Cognitive Impairment - Pipeline by Neuralstem, Inc., H2 2016
  • Cognitive Impairment - Pipeline by Neuron Biopharma SA, H2 2016
  • Cognitive Impairment - Pipeline by NLS Pharma Group, H2 2016
  • Cognitive Impairment - Pipeline by Octapharma AG, H2 2016
  • Cognitive Impairment - Pipeline by Omeros Corporation, H2 2016
  • Cognitive Impairment - Pipeline by Pacific Northwest Biotechnology, LLC, H2 2016
  • Cognitive Impairment - Pipeline by Panacea Pharmaceuticals, Inc., H2 2016
  • Cognitive Impairment - Pipeline by Pfizer Inc., H2 2016
  • Cognitive Impairment - Pipeline by Pherin Pharmaceuticals, Inc., H2 2016
  • Cognitive Impairment - Pipeline by Sage Therapeutics, Inc., H2 2016
  • Cognitive Impairment - Pipeline by Saniona AB, H2 2016
  • Cognitive Impairment - Pipeline by SeneXta Therapeutics SA, H2 2016
  • Cognitive Impairment - Pipeline by Shire Plc, H2 2016
  • Cognitive Impairment - Pipeline by SK Biopharmaceuticals Co., Ltd., H2 2016
  • Cognitive Impairment - Pipeline by Spherium Biomed S.L., H2 2016
  • Cognitive Impairment - Pipeline by Sunovion Pharmaceuticals Inc., H2 2016
  • Cognitive Impairment - Pipeline by Suven Life Sciences Ltd., H2 2016
  • Cognitive Impairment - Pipeline by Takeda Pharmaceutical Company Limited, H2 2016
  • Cognitive Impairment - Pipeline by Tetra Discovery Partners LLC, H2 2016
  • Cognitive Impairment - Pipeline by Therapix Biosciences Ltd., H2 2016
  • Cognitive Impairment - Pipeline by Vanda Pharmaceuticals Inc., H2 2016
  • Cognitive Impairment - Pipeline by Vicore Pharma AB, H2 2016
  • Cognitive Impairment - Pipeline by Virogenomics BioDevelopment, Inc., H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Cognitive Impairment - Dormant Projects, H2 2016
  • Cognitive Impairment - Dormant Projects (Contd..1), H2 2016
  • Cognitive Impairment - Dormant Projects (Contd..2), H2 2016
  • Cognitive Impairment - Dormant Projects (Contd..3), H2 2016
  • Cognitive Impairment - Dormant Projects (Contd..4), H2 2016
  • Cognitive Impairment - Dormant Projects (Contd..5), H2 2016
  • Cognitive Impairment - Dormant Projects (Contd..6), H2 2016
  • Cognitive Impairment - Dormant Projects (Contd..7), H2 2016
  • Cognitive Impairment - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Cognitive Impairment, H2 2016
  • Number of Products under Development for Cognitive Impairment - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top